Lv64
2048 积分 2024-04-22 加入
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
6天前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
14天前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
14天前
已完结
Gastric Cancer
1个月前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
4个月前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
4个月前
已完结
[Mechanism and management of cancer chemotherapy-induced gastrointestinal mucosa damage]
8个月前
已完结
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
9个月前
已完结
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
9个月前
已关闭
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
9个月前
已完结
皖公网安备34019202002308
